| scholarly article | Q13442814 |
| P50 | author | Harold E. Varmus | Q295691 |
| Elaine Mardis | Q5353251 | ||
| George Weinstock | Q5546130 | ||
| Eric Lander | Q970550 | ||
| Richard K. Wilson | Q16193441 | ||
| Marc Ladanyi | Q28468944 | ||
| Brad Ozenberger | Q32414699 | ||
| Gad Getz | Q32646381 | ||
| Wendy Winckler | Q32646521 | ||
| Heidi Greulich | Q32646847 | ||
| Stacey Gabriel | Q32649203 | ||
| Frances A. Shepherd | Q27430461 | ||
| William Pao | Q28025149 | ||
| Carrie Sougnez | Q28321195 | ||
| Matthew Meyerson | Q47451221 | ||
| Ming-Sound Tsao | Q47492209 | ||
| Aldi Kraja | Q114291517 | ||
| Margaret B Morgan | Q115165680 | ||
| Alex H Ramos | Q123348827 | ||
| Mark Rubin | Q37375521 | ||
| John McPherson | Q37391589 | ||
| Mark G Kris | Q37621431 | ||
| Andrew C. Chang | Q37621533 | ||
| Thomas Giordano | Q37621567 | ||
| Alex Lash | Q37621599 | ||
| Hanna Wallach | Q44651811 | ||
| Valerie W Rusch | Q51775643 | ||
| Akihiko Yoshizawa | Q57696572 | ||
| John Minna | Q59751541 | ||
| Richard A Gibbs | Q64856497 | ||
| Ignacio I Wistuba | Q74766086 | ||
| David G Beer | Q87761086 | ||
| Margaret Spitz | Q87847501 | ||
| Rameen Beroukhim | Q88043871 | ||
| Michael A Province | Q88244370 | ||
| Roel G W Verhaak | Q88447576 | ||
| Ingrid B Borecki | Q89095223 | ||
| Sven Perner | Q89425842 | ||
| Levi A Garraway | Q89916155 | ||
| David A. Wheeler | Q91473919 | ||
| Lucian R Chirieac | Q92353485 | ||
| Jack A Roth | Q104479118 | ||
| Barbara A Weir | Q106967220 | ||
| Mark B. Orringer | Q112545944 | ||
| Maureen F Zakowski | Q114291510 | ||
| Adi F Gazdar | Q114291514 | ||
| Qunyuan Zhang | Q114291516 | ||
| P2093 | author name string | James Robinson | |
| Li Ding | |||
| Roman K Thomas | |||
| William D Travis | |||
| Bruce E Johnson | |||
| Derek Y Chiang | |||
| Laura A Johnson | |||
| Michele S Woo | |||
| Neal Lindeman | |||
| Justine A Barletta | |||
| Ling Lin | |||
| Stephen Broderick | |||
| Kinjal Shah | |||
| Mark A Watson | |||
| Mitsuo Sato | |||
| Yoshitaka Fujii | |||
| Hidefumi Sasaki | |||
| William M Lin | |||
| Mark Nadel | |||
| John R Osborne | |||
| Jeonghee Cho | |||
| Soyoung Yu | |||
| David Twomey | |||
| P2860 | cites work | Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells | Q24313496 |
| High-resolution genomic profiles of human lung cancer | Q24530598 | ||
| The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 | ||
| A census of human cancer genes | Q24647081 | ||
| Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application | Q24803815 | ||
| Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos | Q28511927 | ||
| In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 | ||
| GenePattern 2.0 | Q29614171 | ||
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma | Q29614282 | ||
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
| High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays | Q29615979 | ||
| Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo | Q29616612 | ||
| PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing | Q29618564 | ||
| Genome-wide analysis of DNA copy-number changes using cDNA microarrays | Q29618942 | ||
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma | Q30014823 | ||
| dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data | Q30899629 | ||
| Analysis of array CGH data: from signal ratio to gain and loss of DNA regions | Q30961366 | ||
| A comparison of normalization methods for high density oligonucleotide array data based on variance and bias | Q27860710 | ||
| Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection | Q27860727 | ||
| Primer3 on the WWW for general users and for biologist programmers | Q27861030 | ||
| Detection of large-scale variation in the human genome | Q28131803 | ||
| Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung | Q28208680 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer | Q47407029 | ||
| Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer | Q33241239 | ||
| A survey of homozygous deletions in human cancer genomes | Q33934322 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer | Q34444611 | ||
| Chromosomal imbalances in human lung cancer | Q34935902 | ||
| High-resolution analysis of DNA copy number using oligonucleotide microarrays | Q35728773 | ||
| Somatic alterations in the human cancer genome | Q35948400 | ||
| Targeted cancer therapy | Q35953128 | ||
| NCI-Navy Medical Oncology Branch cell line data base | Q36819549 | ||
| Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas | Q38305358 | ||
| High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. | Q40368368 | ||
| Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis | Q40402337 | ||
| Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. | Q40478581 | ||
| An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays | Q40559185 | ||
| Thyroid transcription factor-1 | Q41756471 | ||
| p53: a frequent target for genetic abnormalities in lung cancer | Q52486321 | ||
| Intermediate filament and cross-linked envelope expression in human lung tumor cell lines | Q53545537 | ||
| Frequent amplification of the telomerase reverse transcriptase gene in human tumors | Q58862023 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7171 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| adenocarcinoma of the lung | Q843799 | ||
| P304 | page(s) | 893-898 | |
| P577 | publication date | 2007-11-04 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Characterizing the cancer genome in lung adenocarcinoma | |
| P478 | volume | 450 |
| Q33405641 | "GenotypeColour": colour visualisation of SNPs and CNVs |
| Q36746536 | A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients |
| Q28756297 | A DNA transposon-based approach to validate oncogenic mutations in the mouse |
| Q33918887 | A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas |
| Q38971884 | A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression. |
| Q34994365 | A bioinformatics workflow for variant peptide detection in shotgun proteomics |
| Q34065944 | A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. |
| Q35032336 | A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype |
| Q35878807 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets |
| Q39845869 | A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival |
| Q39123357 | A genomics-based classification of human lung tumors |
| Q45105312 | A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors |
| Q33854958 | A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma |
| Q33618157 | A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer |
| Q27851728 | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response |
| Q38213074 | A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests |
| Q37281454 | A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth |
| Q34478770 | A pilot characterization of human lung NSCLC by protein pathway activation mapping |
| Q27349135 | A role for E2F activities in determining the fate of Myc-induced lymphomagenesis |
| Q33698545 | A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data |
| Q52562647 | A step-by-step microRNA guide to cancer development and metastasis. |
| Q37158337 | A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers |
| Q35033300 | ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time |
| Q38863719 | ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features |
| Q64061654 | APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors |
| Q37667783 | Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients |
| Q34809743 | Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis |
| Q84840731 | Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis |
| Q34271693 | Absolute quantification of somatic DNA alterations in human cancer |
| Q31165447 | Accessing and integrating data and knowledge for biomedical research. |
| Q50893401 | Activation of NF-κB by SOD2 promotes the aggressiveness of lung adenocarcinoma by modulating NKX2-1-mediated IKKβ expression |
| Q35077627 | Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. |
| Q53264472 | Advances in the preclinical testing of cancer therapeutic hypotheses |
| Q30014827 | Advances in understanding cancer genomes through second-generation sequencing |
| Q54350584 | Advances on driver oncogenes of squamous cell lung cancer |
| Q87392676 | Advancing Personalized Cancer Medicine in Lung Cancer |
| Q35123202 | Advancing a clinically relevant perspective of the clonal nature of cancer |
| Q34536679 | Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes |
| Q33754744 | Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer |
| Q35964699 | Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers |
| Q37561673 | Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma |
| Q33708516 | Amplification of chromosomal segment 4q12 in non-small cell lung cancer |
| Q41837923 | Amplification of chromosome 8 genes in lung cancer |
| Q48115878 | An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. |
| Q35027068 | An emerging place for lung cancer genomics in 2013. |
| Q36002695 | An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. |
| Q37294205 | An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors |
| Q33728558 | An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. |
| Q33514281 | An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer |
| Q47770082 | Analysis and Annotation of Whole-Genome or Whole-Exome Sequencing Derived Variants for Clinical Diagnosis |
| Q43590500 | Analysis and annotation of whole-genome or whole-exome sequencing-derived variants for clinical diagnosis |
| Q50936062 | Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma |
| Q53286403 | Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways |
| Q37178620 | Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. |
| Q33842160 | Application of Biomarkers in Cancer Risk Management: Evaluation from Stochastic Clonal Evolutionary and Dynamic System Optimization Points of View |
| Q37204679 | Applications of genomics in melanoma oncogene discovery |
| Q34169994 | Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma |
| Q30014823 | Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma |
| Q58592626 | Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival |
| Q36692818 | BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. |
| Q57734316 | BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros |
| Q37379574 | BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. |
| Q34074628 | Basic principles and technologies for deciphering the genetic map of cancer. |
| Q26801431 | Benign Hereditary Chorea: An Update |
| Q53016537 | Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma |
| Q54570290 | Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments |
| Q37988924 | Biomarkers and transcriptome profiling of lung cancer |
| Q34586762 | Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer |
| Q103803788 | CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer |
| Q33836308 | CDCOCA: a statistical method to define complexity dependence of co-occuring chromosomal aberrations |
| Q28294122 | CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity |
| Q36414685 | CDX2 is an amplified lineage-survival oncogene in colorectal cancer |
| Q33815609 | CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells |
| Q37699447 | CLDN1 expression in cervical cancer cells is related to tumor invasion and metastasis |
| Q33520628 | CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data |
| Q40015369 | CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? |
| Q38868654 | CUL2 is required for the activity of hypoxia-inducible factor and vasculogenesis |
| Q34680398 | CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma |
| Q24607064 | CaSNP: a database for interrogating copy number alterations of cancer genome from SNP array data |
| Q26777117 | Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts |
| Q36481954 | Cancer Genes in Lung Cancer: Racial Disparities: Are There Any? |
| Q57611157 | Cancer Sequencing Gets a Little More Personal |
| Q34962407 | Cancer gene discovery in mouse and man. |
| Q37379481 | Cancer genome sequencing: a review |
| Q33509293 | Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1. |
| Q37503954 | Cell line modeling for systems medicine in cancers (review). |
| Q36296457 | Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study |
| Q63505226 | Characterization of Nine Cancer-Associated Variants in Human DNA Polymerase κ |
| Q37706941 | Characterization of RNA editome in primary and metastatic lung adenocarcinomas. |
| Q37346462 | Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients |
| Q33338286 | Characterization of three new serous epithelial ovarian cancer cell lines |
| Q37146877 | Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer |
| Q38010806 | Chemotherapy and targeted agents for thymic malignancies |
| Q33781119 | Chromosomal and genomic changes in lung cancer |
| Q35088103 | Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent |
| Q41487356 | Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis |
| Q35812982 | Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies |
| Q35239623 | Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer |
| Q34488700 | Clinical Implications of the Cancer Genome |
| Q36343255 | Clinical Integration of Next-Generation Sequencing Technology |
| Q40152155 | Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer |
| Q34610381 | Clinical characteristics and course of 63 patients with BRAF mutant lung cancers |
| Q27851458 | Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma |
| Q37146673 | Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer |
| Q33641395 | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study |
| Q36566531 | Clonal evolution and therapeutic resistance in solid tumors |
| Q37148663 | Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes |
| Q34534035 | Comparative Analysis of Methods for Identifying Recurrent Copy Number Alterations in Cancer |
| Q30771291 | Comparative analysis of methods for identifying somatic copy number alterations from deep sequencing data |
| Q34979403 | Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery |
| Q37112499 | Comparing whole genomes using DNA microarrays |
| Q24631412 | Complex landscapes of somatic rearrangement in human breast cancer genomes |
| Q37589830 | Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum |
| Q37601875 | Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases |
| Q24607126 | Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes |
| Q33966943 | Comprehensive mapping of the human kinome to epidermal growth factor receptor signaling |
| Q28244995 | Comprehensive molecular profiling of lung adenocarcinoma |
| Q47664589 | Computational approaches for discovery of mutational signatures in cancer. |
| Q28080523 | Computational characterisation of cancer molecular profiles derived using next generation sequencing |
| Q57435272 | Consistent testing for recurrent genomic aberrations: Table 1 |
| Q36971430 | Control of Alveolar Differentiation by the Lineage Transcription Factors GATA6 and HOPX Inhibits Lung Adenocarcinoma Metastasis |
| Q35579313 | Conversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction |
| Q36778107 | Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors. |
| Q34117394 | Copy number analysis identifies novel interactions between genomic loci in ovarian cancer |
| Q52851946 | Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases |
| Q34362824 | Copy number expansion of the STX17 duplication in melanoma tissue from Grey horses |
| Q38381518 | Copy number variation in archival melanoma biopsies versus benign melanocytic lesions. |
| Q37245547 | Copy number variations and cancer |
| Q37642520 | Copy number variations and cancer susceptibility |
| Q46031160 | Correction: Somatic mutations in cancer development. |
| Q84582224 | Current challenges in lung cancer early detection biomarkers |
| Q39387419 | DNA repair gene deficiency does not predispose human bronchial epithelial cells to benzo(a)pyrene-induced cell transformation |
| Q35793089 | Deconvolving heterogeneity in the CD8+ T-cell response to HIV. |
| Q34193882 | Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity |
| Q34505542 | Deep clonal profiling of formalin fixed paraffin embedded clinical samples |
| Q35153864 | Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine |
| Q34470961 | Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis |
| Q38696195 | Defining a Cancer Dependency Map. |
| Q37834359 | Defining the cancer master switch |
| Q36030770 | Delving into somatic variation in sporadic melanoma |
| Q54642118 | Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example. |
| Q93137190 | Detection of Local DNA Copy Number Changes in Lung Cancer Population Analyses Using A Multi-Scale Approach |
| Q33999386 | Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons |
| Q37384126 | Detection of recurrent copy number alterations in the genome: taking among-subject heterogeneity seriously |
| Q33658568 | Determining frequent patterns of copy number alterations in cancer |
| Q28382911 | Developing a tissue resource to characterize the genome of pancreatic cancer |
| Q35197454 | Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. |
| Q35555483 | Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors |
| Q40144219 | Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a |
| Q52627783 | Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. |
| Q40675065 | Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma |
| Q36814030 | Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. |
| Q28730029 | Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation |
| Q55096489 | Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes. |
| Q37354628 | Diffuse and calcified nodular opacities |
| Q34152841 | Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis |
| Q54577559 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. |
| Q40257398 | Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer. |
| Q28384678 | Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development |
| Q37314999 | Divide and conquer: progress in the molecular stratification of cancer |
| Q37626056 | Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer |
| Q28086796 | Dysregulation of ubiquitin ligases in cancer |
| Q54441930 | EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases |
| Q36485308 | EML4-ALK fusion lung cancer: a rare acquired event |
| Q36872480 | EMu: probabilistic inference of mutational processes and their localization in the cancer genome |
| Q35924241 | EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk |
| Q36727369 | Effects of cancer-associated EPHA3 mutations on lung cancer. |
| Q28387158 | Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma |
| Q48240221 | Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing |
| Q27023830 | Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q34781380 | Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. |
| Q91525435 | Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma |
| Q37329937 | ErbB4 is an upstream regulator of TTF-1 fetal mouse lung type II cell development in vitro |
| Q35943089 | Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma |
| Q54397820 | Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer |
| Q36837569 | Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome |
| Q37738412 | Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients |
| Q54346071 | Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex |
| Q34359274 | Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib |
| Q55430486 | Expression and clinical significance of the thyroid transcription factor 1 in Xuanwei lung adenocarcinoma |
| Q85042699 | Expression of Thyroid Transcription Factor-1 in Malignant Pleural Effusions |
| Q27852395 | Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer |
| Q33481331 | Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis |
| Q39276579 | Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis |
| Q34797092 | Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma |
| Q36984575 | Focal gains of VEGFA and molecular classification of hepatocellular carcinoma |
| Q41691639 | FocalCall: An R Package for the Annotation of Focal Copy Number Aberrations |
| Q33633583 | Fragile genomic sites are associated with origins of replication. |
| Q44608736 | Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose |
| Q36379430 | Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas |
| Q27851615 | Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. |
| Q36010758 | Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing |
| Q26830811 | From modules to medicine: How modular domains and their associated networks can enable personalized medicine |
| Q37236447 | From oncogene to network addiction: the new frontier of cancer genomics and therapeutics |
| Q33368629 | Functional copy-number alterations in cancer |
| Q37999073 | Functional drug-gene interactions in lung cancer. |
| Q88600058 | Functional interaction-based nonlinear models with application to multiplatform genomics data |
| Q24338701 | Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer |
| Q35557782 | GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers |
| Q59265273 | Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer |
| Q26749348 | Gene aberrations for precision medicine against lung adenocarcinoma |
| Q36839018 | Gene expression profiling of non-small cell lung cancer |
| Q31156446 | GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data |
| Q36115735 | Genetic Changes in Squamous Cell Lung Cancer: A Review |
| Q38255066 | Genetic alterations of protein tyrosine phosphatases in human cancers |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q37855515 | Genetic and epigenetic changes in lung carcinoma and their clinical implications |
| Q35117258 | Genetic architecture of cancer and other complex diseases: lessons learned and future directions |
| Q26865529 | Genetic characteristics and research progress of targeted therapy in squamous cell carcinoma |
| Q42365255 | Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer |
| Q34422582 | Genetic determinants at the interface of cancer and neurodegenerative disease |
| Q37364112 | Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential |
| Q28264870 | Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor |
| Q40048374 | Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery |
| Q37310665 | Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis |
| Q36446169 | Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. |
| Q38975552 | Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. |
| Q28385454 | Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma |
| Q37706305 | Genome wide copy number analyses of superficial esophageal squamous cell carcinoma with and without metastasis |
| Q34126690 | Genome-wide analyses of Nkx2-1 binding to transcriptional target genes uncover novel regulatory patterns conserved in lung development and tumors |
| Q37212218 | Genome-wide analysis of survival in early-stage non-small-cell lung cancer |
| Q37599640 | Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. |
| Q62719029 | Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays |
| Q62785321 | Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer |
| Q34354428 | Genome-wide identification of significant aberrations in cancer genome. |
| Q28385032 | Genomic Aberrations in Lung Adenocarcinoma in Never Smokers |
| Q33569956 | Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway |
| Q39756938 | Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma |
| Q38543407 | Genomic alterations in lung adenocarcinoma |
| Q37276772 | Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia |
| Q37824622 | Genomic and epigenetic profiles of gastric cancer: Potential diagnostic and therapeutic applications |
| Q35873554 | Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer |
| Q35036588 | Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status |
| Q53264465 | Genomic characterization of asymptomatic CT-detected lung cancers. |
| Q35085978 | Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes |
| Q64064796 | Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung |
| Q36851245 | Genomic landscape of non-small cell lung cancer in smokers and never-smokers |
| Q33340988 | Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer |
| Q24610167 | Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer |
| Q43174336 | Genomic profiling of prostate cancers from African American men. |
| Q37863628 | Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy |
| Q58804574 | Genomics of adult and pediatric solid tumors |
| Q26851787 | Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies |
| Q37171910 | Genomics of lung cancer. |
| Q36440719 | Getting DNA copy numbers without control samples. |
| Q91726622 | Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization |
| Q37815124 | Haplo-insufficiency: a driving force in cancer |
| Q37790599 | Harnessing the immune response to treat cancer |
| Q35973988 | Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence |
| Q36414198 | High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer. |
| Q28476277 | High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507) |
| Q34414476 | High throughput mass spectrometry-based mutation profiling of primary uveal melanoma |
| Q44188218 | High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. |
| Q37109744 | High-content analysis of cancer genome DNA alterations |
| Q89555553 | High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations |
| Q35096589 | High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. |
| Q33440056 | High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors |
| Q80856831 | High-resolution genomic and expression analyses of copy number alterations in breast tumors |
| Q34050186 | High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes |
| Q34541232 | High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated |
| Q37068513 | Highly parallel identification of essential genes in cancer cells |
| Q27312570 | Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics |
| Q37466158 | Homozygous inactivating mutations in the NKX3-2 gene result in spondylo-megaepiphyseal-metaphyseal dysplasia |
| Q37065678 | How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers |
| Q33554201 | Human cancers express mutator phenotypes: origin, consequences and targeting |
| Q37385838 | Hybridization modeling of oligonucleotide SNP arrays for accurate DNA copy number estimation. |
| Q30351902 | Hypothesis driven single nucleotide polymorphism search (HyDn-SNP-S). |
| Q38659248 | ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection |
| Q35631086 | IGDB.NSCLC: integrated genomic database of non-small cell lung cancer |
| Q30877356 | Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells |
| Q34207099 | Identification of DOK genes as lung tumor suppressors |
| Q35032328 | Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer |
| Q37262522 | Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen |
| Q39035797 | Identification of ZDHHC14 as a novel human tumour suppressor gene. |
| Q38762535 | Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation |
| Q36011694 | Identification of cancer-driver genes in focal genomic alterations from whole genome sequencing data |
| Q55027358 | Identification of copy number alterations in colon cancer from analysis of amplicon-based next generation sequencing data. |
| Q34504751 | Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers |
| Q64941057 | Identification of key pathways and genes in lung carcinogenesis. |
| Q35152155 | Identification of logic relationships between genes and subtypes of non-small cell lung cancer. |
| Q33705551 | Identification of lung cancer with high sensitivity and specificity by blood testing |
| Q35166315 | Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. |
| Q38717741 | Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. |
| Q35256884 | Identification of regulatory SNPs associated with genetic modifications in lung adenocarcinoma. |
| Q98177113 | Identification of relevant genetic alterations in cancer using topological data analysis |
| Q34787147 | Identification of the NEDD4L Gene as a Prognostic Marker by Integrated Microarray Analysis of Copy Number and Gene Expression Profiling in Non-small Cell Lung Cancer |
| Q42513461 | Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth |
| Q41090797 | Identifying CDKN3 Gene Expression as a Prognostic Biomarker in Lung Adenocarcinoma via Meta-analysis. |
| Q26781810 | Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer |
| Q36050371 | Imaging of Lung Cancer in the Era of Molecular Medicine |
| Q38323055 | Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? |
| Q33988646 | Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. |
| Q36331013 | In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids |
| Q37355404 | In vivo/ex vivo and in situ assays used in cancer research: a brief review |
| Q34993692 | Increased BRAF copy number in lung adenocarcinoma |
| Q35926926 | Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients |
| Q86073879 | Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma |
| Q37980724 | Inhibition and Termination of Physiological Responses by GTPase Activating Proteins |
| Q64895040 | Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells. |
| Q27851654 | Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer |
| Q36240493 | Integrated Analysis of Genome-Wide Copy Number Alterations and Gene Expression Profiling of Lung Cancer in Xuanwei, China |
| Q36894394 | Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. |
| Q52629222 | Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion |
| Q34026325 | Integrated analyses of copy number variations and gene expression in lung adenocarcinoma |
| Q24649562 | Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers |
| Q36592406 | Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target |
| Q60910638 | Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma |
| Q34786771 | Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis |
| Q36152246 | Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer |
| Q90715196 | Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis |
| Q35837786 | Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer |
| Q43889503 | Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. |
| Q33644421 | Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma |
| Q37216672 | Integrative genomic approaches to understanding cancer. |
| Q29619905 | Integrative genomic profiling of human prostate cancer |
| Q39134067 | Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression |
| Q28303718 | International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma |
| Q35219746 | Intersections between Pulmonary Development and Disease |
| Q91649995 | Intratumor Heterogeneity in Early Lung Adenocarcinoma |
| Q38356968 | Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity |
| Q24570128 | Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls |
| Q33557528 | JISTIC: identification of significant targets in cancer. |
| Q37384068 | KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. |
| Q28242884 | KRAS mutant allele-specific imbalance in lung adenocarcinoma |
| Q36464999 | KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis |
| Q92003211 | Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation |
| Q24303485 | Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung |
| Q37850361 | LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor |
| Q39101598 | LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas |
| Q36865568 | LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma |
| Q37377962 | Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome |
| Q44292546 | Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma |
| Q55485409 | Landscape of transcriptional deregulation in lung cancer. |
| Q38094259 | Lessons from the Cancer Genome |
| Q36943760 | Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines |
| Q38395972 | Lineage factors and differentiation states in lung cancer progression |
| Q35565689 | Losing balance: Hardy-Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer |
| Q33956097 | Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression |
| Q37708984 | Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. |
| Q37428082 | Loss-of-function of an Arabidopsis NADPH pyrophosphohydrolase, AtNUDX19, impacts on the pyridine nucleotides status and confers photooxidative stress tolerance. |
| Q34281228 | Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases |
| Q82448154 | Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains |
| Q34110617 | Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research |
| Q34193618 | Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability |
| Q51081160 | Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. |
| Q28754732 | Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research |
| Q37487153 | Lung cancer biology: a genetic and genomic perspective. |
| Q35033316 | Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? |
| Q37023811 | Lung cancer in never smokers: a call to action |
| Q34177155 | Lung cancer in never smokers: molecular profiles and therapeutic implications |
| Q35861107 | Lung cancer in the era of precision medicine |
| Q35636924 | Lung cancer mutations and use of targeted agents in Hispanics |
| Q24628852 | Lung cancer signatures in plasma based on proteome profiling of mouse tumor models |
| Q34094849 | Lung cancer: developmental networks gone awry? |
| Q34432733 | Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor. |
| Q99608553 | MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs |
| Q24646295 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib |
| Q24297454 | MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis |
| Q36166125 | MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer |
| Q33820617 | MYCxing it up with FGFR1 in squamous cell lung cancer |
| Q64136466 | MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC |
| Q89777623 | Maintenance of telomere length in AML |
| Q33329722 | Major copy proportion analysis of tumor samples using SNP arrays |
| Q33846850 | Making sense of cancer genomic data |
| Q28275103 | Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing |
| Q38010665 | Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations |
| Q39911616 | Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer |
| Q47735795 | Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers |
| Q52617931 | Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene. |
| Q47761912 | Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. |
| Q34241853 | MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1 |
| Q37702742 | MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status |
| Q39041572 | MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. |
| Q36910037 | MicroRNA-33a Mediates the Regulation of High Mobility Group AT-Hook 2 Gene (HMGA2) by Thyroid Transcription Factor 1 (TTF-1/NKX2–1) |
| Q38005062 | MicroRNAs and lung cancers: from pathogenesis to clinical implications |
| Q42833899 | Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells |
| Q39210492 | Molecular Dissection of AKT Activation in Lung Cancer Cell Lines |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q33468458 | Molecular characterization of lung dysplasia induced by c-Raf-1. |
| Q56795277 | Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay |
| Q38716717 | Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis |
| Q37200438 | Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma |
| Q37919395 | Molecular oncology of lung cancer |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q34608584 | Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer |
| Q54648969 | Morphological and molecular pathology of lung cancer |
| Q34205443 | Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. |
| Q38245669 | Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer |
| Q37150862 | MtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints. |
| Q96128436 | Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics |
| Q28237604 | Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma |
| Q82905302 | Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients |
| Q35382936 | Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma |
| Q36031579 | Mutational heterogeneity in human cancers: origin and consequences. |
| Q37385138 | Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma |
| Q37369422 | Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma |
| Q24338837 | NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor |
| Q37957618 | NKL homeobox genes in leukemia. |
| Q58695806 | NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration |
| Q35987328 | NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation |
| Q24308684 | NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma |
| Q38114206 | NKX2-1/TTF-1: An Enigmatic Oncogene that Functions as a Double-Edged Sword for Cancer Cell Survival and Progression |
| Q24317081 | NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation |
| Q34428676 | NOTCH1, HIF1A and Other Cancer-Related Proteins in Lung Tissue from Uranium Miners—Variation by Occupational Exposure and Subtype of Lung Cancer |
| Q44337507 | Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung |
| Q40725339 | Network-Based Logistic Classification with an Enhanced L 1/2 Solver Reveals Biomarker and Subnetwork Signatures for Diagnosing Lung Cancer |
| Q37340439 | New applications and developments in the use of multiplex ligation-dependent probe amplification |
| Q34161395 | New driver mutations in non-small-cell lung cancer |
| Q42271046 | New lung cancer panel for high-throughput targeted resequencing |
| Q21183966 | New strategies and emerging technologies for massively parallel sequencing: applications in medical research |
| Q34544846 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial |
| Q36458217 | Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics |
| Q37138662 | Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance |
| Q37041088 | Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma |
| Q26995181 | Nkx2-1: a novel tumor biomarker of lung cancer |
| Q49787050 | Nkx2-3-A Slippery Slope From Development Through Inflammation Toward Hematopoietic Malignancies. |
| Q36217272 | Occludin Is a Direct Target of Thyroid Transcription Factor-1 (TTF-1/NKX2–1) |
| Q27023347 | Omics of Cancer |
| Q33510334 | Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells |
| Q28082384 | Oncogenic Signaling Adaptor Proteins |
| Q27852873 | Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma |
| Q38213830 | Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer |
| Q27023342 | One mouse, one patient paradigm: New avatars of personalized cancer therapy |
| Q37410396 | One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation. |
| Q48632489 | Opposite roles of FOXA1 and NKX2-1 in lung cancer progression |
| Q40844290 | Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays |
| Q38073157 | Other signalization targets |
| Q35368205 | Our changing view of the genomic landscape of cancer |
| Q34612346 | Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis |
| Q38578968 | Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer |
| Q64280891 | PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors |
| Q92497822 | PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer |
| Q33511182 | PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data |
| Q64053991 | PITX2 enhances progression of lung adenocarcinoma by transcriptionally regulating WNT3A and activating Wnt/β-catenin signaling pathway |
| Q60922787 | PSPH Mediates the Metastasis and Proliferation of Non-small Cell Lung Cancer through MAPK Signaling Pathways |
| Q28240702 | PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR |
| Q37666205 | Pan-cancer patterns of somatic copy number alteration |
| Q44748335 | Parallel evolution of tumour subclones mimics diversity between tumours |
| Q37389526 | Pathogenesis of lung cancer signalling pathways: roadmap for therapies |
| Q48322740 | Paul Ehrlich's magic bullet concept: 100 years of progress |
| Q35037810 | Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data |
| Q37909661 | Personalized Therapy for Non–Small Cell Lung Cancer: Hype or Clinical Reality? |
| Q37776547 | Personalized therapies in the cancer "omics" era |
| Q37080513 | Personalizing lung cancer prevention through a reverse migration strategy |
| Q35058948 | Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema |
| Q37620148 | Polycomb group proteins: navigators of lineage pathways led astray in cancer |
| Q37327531 | Precise inference of copy number alterations in tumor samples from SNP arrays |
| Q37742635 | Precision medicine driven by cancer systems biology |
| Q37209222 | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions |
| Q37695981 | Preprocessing and downstream analysis of microarray DNA copy number profiles |
| Q92107648 | Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region |
| Q34171479 | Principles and strategies for developing network models in cancer |
| Q33692550 | Probability Theory-Based SNP Association Study Method for Identifying Susceptibility Loci and Genetic Disease Models in Human Case-Control Data |
| Q30694445 | Progenetix: 12 years of oncogenomic data curation |
| Q36060090 | Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status |
| Q30497419 | Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer |
| Q38493294 | Prognostic and predictive value of MET deregulation in non-small cell lung cancer |
| Q40155594 | Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. |
| Q36141851 | Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4 |
| Q37775627 | Prospects for molecular staging of non-small-cell lung cancer from genomic alterations |
| Q27307731 | Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer |
| Q53269470 | Protein tyrosine phosphatases receptor type D is a potential tumour suppressor gene inactivated by deoxyribonucleic acid methylation in paediatric acute myeloid leukaemia |
| Q28395348 | Pulmonary adenocarcinoma: A renewed entity in 2011 |
| Q91676950 | RB constrains lineage fidelity and multiple stages of tumour progression and metastasis |
| Q92542047 | Ras Downstream Effector GGCT Alleviates Oncogenic Stress |
| Q34773458 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer |
| Q38643392 | Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma |
| Q52653017 | Recurrent copy number alterations in young women with breast cancer. |
| Q64044073 | Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease |
| Q33472669 | Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer |
| Q34550261 | Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma |
| Q53121013 | Reflections on the Founding of the International Cancer Genome Consortium |
| Q28603652 | Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers |
| Q38004927 | Regulation of Parkin E3 ubiquitin ligase activity. |
| Q39384713 | Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. |
| Q36650250 | Regulation of Transient Site-specific Copy Gain by MicroRNA. |
| Q53233695 | Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. |
| Q38164307 | Regulatory variation: an emerging vantage point for cancer biology |
| Q34637846 | Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer |
| Q54333038 | Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients |
| Q35063579 | Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients |
| Q26826821 | Research progress of thyroid transcription factor-1 as molecular marker in lung carcinoma |
| Q35668629 | Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. |
| Q37956397 | Role of genotyping in non-small cell lung cancer treatment: current status |
| Q36953349 | SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling |
| Q28587694 | SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism |
| Q57693361 | SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer |
| Q30491937 | SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas |
| Q90043990 | SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p |
| Q34176566 | Secretoglobin 3A2/uteroglobin-related protein 1 is a novel marker for pulmonary carcinoma in mice and humans |
| Q33367138 | Segmental duplications arise from Pol32-dependent repair of broken forks through two alternative replication-based mechanisms |
| Q33312522 | Sex, dose, and equality |
| Q90609854 | ShinyCNV: a Shiny/R application to view and annotate DNA copy number variations |
| Q38974422 | Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer |
| Q34143340 | Should we continue to use the term non-small-cell lung cancer? |
| Q39737975 | Signatures of mutation and selection in the cancer genome |
| Q36886177 | Significant frequency of allelic imbalance in 3p region covering RARβ and MLH1 loci seems to be essential in molecular non-small cell lung cancer diagnosis |
| Q33934743 | Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide |
| Q33902184 | Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression |
| Q39127721 | Sirt3 is a tumor suppressor in lung adenocarcinoma cells |
| Q39565398 | Small-molecule binding sites to explore protein-protein interactions in the cancer proteome |
| Q37287242 | Smoking-related genomic signatures in non-small cell lung cancer |
| Q36214274 | Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. |
| Q24648102 | Somatic mutations affect key pathways in lung adenocarcinoma |
| Q42713219 | Somatic mutations in cancer development |
| Q39009613 | Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies |
| Q34073818 | Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. |
| Q34442770 | Spatial and temporal diversity in genomic instability processes defines lung cancer evolution |
| Q37236636 | Specificity in cancer immunotherapy |
| Q28742090 | Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers |
| Q47715326 | Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. |
| Q36909843 | Squamous Cell Cancers: A Unified Perspective on Biology and Genetics |
| Q27026425 | Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities |
| Q37132800 | State of the art in tumor antigen and biomarker discovery. |
| Q42273036 | Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene |
| Q34163784 | Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification |
| Q38035556 | Structural mutations in cancer: mechanistic and functional insights |
| Q27680966 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer |
| Q35008652 | SubPatCNV: approximate subspace pattern mining for mapping copy-number variations |
| Q34939788 | Suppression of lung adenocarcinoma progression by Nkx2-1 |
| Q35134003 | Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer |
| Q34345632 | TAGCNA: A Method to Identify Significant Consensus Events of Copy Number Alterations in Cancer |
| Q35370365 | TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer |
| Q27851543 | TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. |
| Q48247270 | TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas. |
| Q34754045 | Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. |
| Q37851009 | Taming the dragon: genomic biomarkers to individualize the treatment of cancer. |
| Q57327189 | Targeted Genomic Screen Reveals Focal Long Non-Coding RNA Copy Number Alterations in Cancer Cell Lines |
| Q34149286 | Targeted Therapies for Thymic Malignancies |
| Q92337932 | Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma |
| Q36928888 | Targeted therapies for hepatocellular carcinoma. |
| Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
| Q37410635 | Targeting SOD1 reduces experimental non–small-cell lung cancer |
| Q33347458 | Telomeres and disease |
| Q35919877 | The 8q24 gene desert: an oasis of non-coding transcriptional activity. |
| Q37132018 | The Complexity of Thyroid Transcription Factor 1 with Both Pro- and Anti-oncogenic Activities |
| Q35400332 | The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling |
| Q40289758 | The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. |
| Q37809678 | The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer |
| Q41891513 | The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies |
| Q34456234 | The UCSC Cancer Genomics Browser: update 2011 |
| Q37018751 | The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development |
| Q36450685 | The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis |
| Q34129229 | The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence |
| Q35083049 | The essential role of evasion from cell death in cancer |
| Q37462617 | The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas |
| Q38296670 | The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer |
| Q29547648 | The landscape of somatic copy-number alteration across human cancers |
| Q37703901 | The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment |
| Q34117627 | The mutation spectrum revealed by paired genome sequences from a lung cancer patient |
| Q35216054 | The potential utility of telomere‐related markers for cancer diagnosis |
| Q36906563 | The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma |
| Q90612096 | The prognostic effect of TTF-1 expression in the Chinese population of patients with advanced lung adenocarcinomas |
| Q37296558 | The role of AUTS2 in neurodevelopment and human evolution |
| Q37900640 | The role of inflammation in the pathogenesis of lung cancer |
| Q28083838 | The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression |
| Q28246658 | The somatic genomic landscape of chromophobe renal cell carcinoma |
| Q36354852 | The transcriptional landscape and mutational profile of lung adenocarcinoma. |
| Q28115840 | The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers |
| Q36615870 | Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. |
| Q82099060 | Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis |
| Q88091776 | Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism |
| Q36642670 | Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer |
| Q35325144 | Thyroid transcription factor-1 (TTF-1) gene: identification of ZBP-89, Sp1, and TTF-1 sites in the promoter and regulation by TNF-α in lung epithelial cells |
| Q64938110 | Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. |
| Q33873336 | Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells |
| Q35038884 | Thyroid-Specific Transcription Factors and Their Roles in Thyroid Cancer |
| Q37118065 | Tight junction proteins: from barrier to tumorigenesis. |
| Q91861384 | Towards quantitative and multiplexed in vivo functional cancer genomics |
| Q28655985 | Tracking genomic cancer evolution for precision medicine: the lung TRACERx study |
| Q28488566 | Transcriptome Sequencing of Tumor Subpopulations Reveals a Spectrum of Therapeutic Options for Squamous Cell Lung Cancer |
| Q34762165 | Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes |
| Q36491120 | Transcriptome sequencing of malignant pleural mesothelioma tumors |
| Q24653386 | Transcriptome sequencing to detect gene fusions in cancer |
| Q36354845 | Translating genomic information into clinical medicine: lung cancer as a paradigm |
| Q54484638 | Translational research and diagnostics in lung cancer |
| Q97538366 | Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer |
| Q38209599 | Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? |
| Q37960077 | Tumor-promoting functions of transforming growth factor-β in progression of cancer. |
| Q40398766 | Tumor-specific immune responses |
| Q33353558 | Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease |
| Q43080951 | Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. |
| Q22241904 | Update in lung cancer 2007 |
| Q37287067 | Update in lung cancer 2008 |
| Q37645219 | Update on biomarkers for the detection of lung cancer. |
| Q35071486 | Use of gene expression and pathway signatures to characterize the complexity of human melanoma |
| Q34175045 | Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs |
| Q46126845 | VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities |
| Q33898563 | Wavelet-based identification of DNA focal genomic aberrations from single nucleotide polymorphism arrays |
| Q81352782 | What oncologists need and require from nuclear medicine |
| Q36972125 | Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. |
| Q34352229 | Whole genome sequencing for lung cancer. |
| Q33688583 | Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis |
| Q33904277 | Why is it crucial to reintegrate pathology into cancer research? |
| Q41900278 | Will we cure cancer by sequencing thousands of genomes? |
| Q37649231 | YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. |
| Q58761037 | and Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients |
| Q21134582 | arrayMap: a reference resource for genomic copy number imbalances in human malignancies |
| Q35238414 | cMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication. |
| Q37529618 | iCAGES: integrated CAncer GEnome Score for comprehensively prioritizing driver genes in personal cancer genomes |
| Q41412761 | miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer |
| Q54385560 | miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells. |
Search more.